Precigen, INC Schedule 13G passive stakes

Several Merck-affiliated entities have jointly filed a Schedule 13G, reporting a combined 4.9% beneficial ownership of Precigen, Inc. common stock.

Point72 Asset Management and Steven A. Cohen have reported a 1.9% beneficial ownership stake in Precigen, Inc. as of March 31, 2026.

Patient Capital Management and Patient Opportunity Trust have increased their beneficial ownership in Precigen, Inc. to 10.18% and 7.8% respectively.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly reported a 5.2% beneficial ownership stake in Precigen, Inc.

Patient Capital Management, LLC and Patient Opportunity Trust have reported a combined beneficial ownership of 24.6% of Precigen, Inc.'s common stock.

The William H. Miller III Living Trust has reported a 9.2% beneficial ownership stake in Precigen, Inc., including shares from exercisable warrants.

Patient Capital Management, LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 6.53% of Precigen, Inc.'s common stock as of December 31, 2024.